Survodutide Research for MASH/NAFLD
An evidence-based overview of research examining Survodutide in the context of mash/nafld. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2 RCT (N=293) showed up to 62% MASH improvement without worsening of fibrosis vs 14% placebo, and up to 36% fibrosis improvement (>=1 stage) vs 22% placebo at 48 weeks. A >=30% reduction in liver fat occurred in 57-67% of survodutide groups vs 14% placebo. Phase 3 development is ongoing.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Survodutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.